drugset / Trial / NCT00823849
Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker
RandomizedParallel-groupOpen-labelTreatment
Summary
1. To evaluate the efficacy of Cilostazol and Probucol alone and in combination on atherosclerosis related biomarker 2. To evaluate the safety of Cilostazol and Probucol alone and in combination on atherosclerosis related biomarker
Timeline
- Start
- 2008-10
- Primary completion
- 2009-08
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cilostazol | Small molecule | 50 mg | Oral |
| Subject | Cilostazol | Small molecule | 100 mg | Oral |
| Subject | Probucol | Small molecule | 250 mg | Oral |